• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

    8.960 +0.170 (+1.93%)
    Streaming Delayed Price Updated: 12:03 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 302,100
    Open 8.770
    Bid (Size) 8.950 (5,000)
    Ask (Size) 9.010 (100)
    Prev. Close 8.790
    Today's Range 8.660 - 9.325
    52wk Range 8.080 - 14.87
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire

    Performance

    YTD
    -27.1%
    -27.1%
    1 Month
    +3.2%
    +3.2%
    3 Month
    -28.6%
    -28.6%
    6 Month
    -20.8%
    -20.8%
    1 Year
    -28.0%
    -28.0%

    More News

    Read More
    News headline image
    BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT to Participate in Upcoming Investor Healthcare Conferences
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT to Participate in Upcoming December Investor Healthcare Conferences
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT to Participate in the Jefferies Global Healthcare Conference in London
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire
    News headline image
    BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
    From TheRas, Inc. (d/b/a BBOT)
    Via GlobeNewswire

    Frequently Asked Questions

    Is BridgeBio Oncology Therapeutics, Inc. - Common Stock publicly traded?
    Yes, BridgeBio Oncology Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does BridgeBio Oncology Therapeutics, Inc. - Common Stock trade on?
    BridgeBio Oncology Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock?
    The ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock is BBOT on the Nasdaq Stock Market
    What is the current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock?
    The current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock is 8.960
    When was BridgeBio Oncology Therapeutics, Inc. - Common Stock last traded?
    The last trade of BridgeBio Oncology Therapeutics, Inc. - Common Stock was at 04/28/26 12:03 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.